The intriguing relationship of helicobacter pylori infection and acid secretion in peptic ulcer disease and gastric cancer

Digestive Diseases

Volumn 29, Issue 5, 2011, Pages 459-464

  Malfertheiner, P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Acid secretion; Gastric cancer; Helicobacter pylori infection; Peptic ulcer disease

Indexed keywords

GASTRIN; GASTRIN 17; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ACHLORHYDRIA; ARTICLE; DISEASE ASSOCIATION; DUODENUM ULCER; GASTRIN RELEASE; GASTRITIS; HELICOBACTER INFECTION; HUMAN; PEPTIC ULCER; PHENOTYPE; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH CANCER; STOMACH PH;

ANIMALS; GASTRIC ACID; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; STOMACH NEOPLASMS;

EID: 81755162866     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000332213     Document Type: Article

References (44)

1. Marshall BJ, Armstrong JA, McGechie DB, et al: Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust 1985; 142: 436-439. (Pubitemid 15233564)
2. Morris A, Nicholson G: Ingestion of Campy-lobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 1987; 82: 192-199. (Pubitemid 17047002)
3. Sobala GM, Crabtree JE, Dixon MF, et al: Acute H. pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991; 32:1415-1418.
4. Ramsey EJ, Carey K V, Peterson WL, et al: Epidemic gastritis with hypochlorhydria. Gastroenterology 1979; 76:1449-1457. (Pubitemid 9183097)
5. Peterson W, Lee E, Skoglund M: The role of Campylobacter pyloridis in epidemic gastritis with hypochlorhydria. Gastroenterology 1987; 92:1575.
6. Graham DY, Alpert LC, Smith JL, et al: Iat-rogenic Campylobacter pylori infection is a cause of epidemic achlorhydria. Am J Gas-troenterol 1988; 83:974-980.
7. Dixon MF, Genta JH, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.
8. Lee A, Dixon MF, Danon SJ, et al: Local acid production and H. pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastro-enterol Hepatol 1995; 7:461-465.
9. Malfertheiner P, Chan FK, McColl KE: Peptic ulcer disease. Lancet 2009; 374: 14 4 9-1461.
10. Malagelada JR, Longstreth GF, Deering TB, Summerskill WH, Go VL: Gastric secretion and emptying after ordinary meals in duodena l ulcer. Gastroenterology 1977; 73: 989-993.
11. Gillen D, El-Omar EM, Wirz AA, Ardill JE, McColl KE: The acid response to gastrin distinguishes duodenal ulcer patients from He-licobacter pylori-infected healthy subjects. Gastroenterology 1998; 114:50-57. (Pubitemid 28020954)
12. Calam J, Levi S, Beardshall K, Playford R, Ghosh P, Swift I, Foulkes W, Haddad G: He-licobacter pylori and duodenal ulcer-the gastrin link; in Malfertheiner P, Ditschuneit H (eds): Helicobacter pylori, Gastritis and Peptic Ulcer. Berlin, Springer, 1990, pp 317-326.
13. Moss SF, Legon S, Bishop AE, et al: Effect of H. pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992; 340: 930-932.
14. Odum I, Petersen HD, Andersen IB, Hansen BF, Rehfeld JF: Gastrin and somatostatin in H. pylori-infected antral mucosa. Gut 1994; 35: 615-618.
15. Levi S, Beardshall K, Haddad G, et al: Cam-pylobacter pylori and duodenal ulcers: the gastrin link. Lancet 1989; 1:1167-1168. (Pubitemid 19138852)
16. Olbe L, Hamlet A, Dalenbäck J, Fändriks L: A mechanism by which H. pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996; 11 0: 1386-1394. (Pubitemid 26134069)
17. Hamlet A, Olbe L: The influence of H. pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. Gas-troenterology 1996; 111: 391-400. (Pubitemid 26256727)
18. El-Omar E, Penman I, Dorrian CA, et al: Eradicating H. pylori infection lowers gas-trin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut 1993; 34: 1060-1065. (Pubitemid 23245355)
19. McColl KEL, Fullarton GM, el Nujumi AM, et al: Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer. Lancet 1989; ii:499-500. (Pubitemid 19209159)
20. McColl KEL, Gillen D, El-Omar E: The role of gastrin in ulcer pathogenesis; in Tytgat GNJ (ed): Baillière's Best Practice and Research. Clinical Gastroenterology and Peptic Ulcer Disease. London, Harcourt, 2000.
21. Malfertheiner P, Stanescu A, Bode G, Bac-zako K, Kühl P, Ditschuneit H: Gastric metaplasia in duodenal mucosa-key factor for H. pylori colonization and duodenal ulcer pathogenesis?; in Malfertheiner P, Ditschuneit H (eds): Helicobacter pylori, Gastritis and Peptic Ulcer. Berlin, Springer, 1990, pp 292-301.
22. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ: Clinical and pathological importance of heterogenicity in vacA, the vacuolating cytotoxin gene of H. pylori. Gastroenterology 1997; 112:92-99. (Pubitemid 27008990)
23. Lu H, Hsu PI, Graham DY, Yamaoka Y: Duodenal ulcer-promoting gene of H. pylori. Gastroenterology 2005; 128: 833-848.
24. Hussein NR, Argent RH, Marx CK, Patel SR Robinson K, Atherton JC: H. pylori dupA is polymorphic, and its active form induces proinflammatory cytokine secretion by mononuclear cells. J Infect Dis 2010; 202: 261-269.
25. Wolfe MM, Nompleggi DJ: Cytokine inhibition of gastric acid secretion-a little goes a long way. Gastroenterology 1992; 102:2177-2178.
26. Beales IL, Calam J: Interleukin-1fS and tumour necrosis factor-a inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998; 42:227-234. (Pubitemid 28212178)
27. El-Omar EM, Penman ID, Ardill JE, et al: H. pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681-691.
28. Saha A, Hammond CE, Beeson C, Peek RM Jr, Smolka AJ: H. pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa. Gut 2010;59:874-881.
29. +-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003; 198: 114 7-115 6.
30. Bergman MP, Vandenbroucke-Grauls CM, Appelmelk BJ, et al: The story so far: H. pylori and gastric autoimmunity. Int Rev Immunol 2005; 24:63-91. (Pubitemid 40069748)
31. Verdu EF, Armstrong D, Idström JP, et al: In-tragastric pH during treatment with omepra-zole: role of H. pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1151-1156. (Pubitemid 26403088)
32. Labenz J, Ti llenburg B, Peitz U, et al: Ef ficacy of omeprazole one year after cure of H. pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576-581. (Pubitemid 27184367)
33. Holt ma nn G, C a in C, Ma l fer t heiner P: H. pylori accelerates healing of reflux oesophagi-tis during the treatment with the proton pump inhibitor pantoprazole. Gastroenter-ology 1999; 11 7: 11-16. (Pubitemid 29297614)
34. Malfertheiner P, Megraud F, O'Morain C, et al: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Repor t. Gut 2007; 56: 772-781. (Pubitemid 46854190)
35. Kuipers EJ, Lundell L, Klinkenberg EC, et al: Atrophic gastritis and H. pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334:1018-1022. (Pubitemid 26123777)
36. Stolte M, Bethke B: Elimination of H. pylori under treatment with omeprazole. Z Gastro-enterol 1990; 28:271-274.
37. Klinkenberg-Knol EC, Nelis F, Dent J, et al: Long-term omeprazole treatment in resistant esophageal ref lux disease: efficacy, safety, and influence on gastric mucosa. Gastro-enterology 2000; 118:661-669. (Pubitemid 30171615)
38. Horii T, Koike T, Abe Y, et al: Two distinct types of cancer of different origin may be mixed in gastroesophageal junction adeno-carcinomas in Japan: evidence from direct evaluation of gastric acid secretion. Scand J Gastroenterol 2011; 46: 710-719.
39. Ohata H, Kitauchi S, Yoshimura N, et al: Progression of chronic atrophic gastritis associated with H. pylori infection increases risk of gastric cancer. Int J Ca ncer 2004; 10 9: 138-143. (Pubitemid 38160674)
40. Varis K, Sipponen P, Laxen F, et al: Implications of serum pepsinogen I in early endo-scopic diagnosis of gastric cancer and dys-plasia. Scand J Gastroenterol 2000; 35: 950-956.
41. Miki K, Fujishiro M, Kodashima S, Yaha-gi N: Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009; 21:78-81.
42. Leung WK, Wu MS, Kakugawa Y, et al: Screening of gastric cancer in Asia: current ev idence and practice. La ncet Oncol 2008; 9: 279-287. (Pubitemid 351722947)
43. Agreus L, Kuipers E, Kupcinskas L, et al: Diagnosis of atrophic gastritis with plasma bio-markers. A review article. Scand J Gastroen-terol (accepted 2011).
44. Kikuchi R, Abe Y, Iijima K, et al: Low serum levels of pepsinogen and gastrin-17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med 2011; 223: 35-44.